About

About CHA Vaccine Institute CHA Vaccine Institute (KOSDAQ: 261780) – Pioneering Next-Generation Vaccines & Immunotherapies CHA Vaccine Institute is a cutting-edge biotechnology company dedicated to developing transformative therapeutic and prophylactic vaccines, as well as innovative cancer immunotherapies. Proprietary Adjuvant Platforms: Our TLR2/TLR3 agonist combination significantly enhances vaccine efficacy and anti-cancer immune responses. Addressing Critical Medical Needs: Targeting high-value markets, including Chronic Hepatitis B ($5.6B) and Herpes Zoster ($5.0B). Robust Clinical Pipeline: Advancing three clinical trials, including a Phase 2b vaccine and two Phase 1 prophylactic vaccines. Strong Intellectual Property Portfolio: Protecting innovation with 40 global patents. Expert Leadership: Led by a team of seasoned biotech professionals driving innovation and growth.